iRhythm Holdings, Inc. (IRTC) stock intrinsic value fair value estimate & owner earnings analysis

iRhythm sells the Zio service: a small adhesive heart monitor worn for up to two weeks, plus the company's algorithm-and-technician analysis that turns the recording into a report for the prescribing doctor. It is paid mainly by commercial insurers and Medicare (about 24% of 2025 revenue) under established billing codes for long-term ECG monitoring. Revenue has grown from $64 million in 2016 to $747 million in 2025, and was $424 million in the first half of 2026, up 23%. Nearly all sales are in the United States, with small but growing business in the United Kingdom, the Netherlands and Japan. What the business earns today. Measured as the cash an owner could take out after paying employees in stock, maintaining equipment, and absorbing the cost of claims that are denied or never collected, iRhythm has not yet earned money in any year. That figure was about -$136 million in 2023, -$82 million in 2024 and -$61 million in 2025 (about -$1.90 per share). Two accounting choices matter here. First, stock compensation ($88 million in 2025) is treated as a real cost. Second, the roughly $100 million a year the company sets aside for denied claims and uncollectable bills is treated as a real cost, not added back. The positive operating cash flow of $81 million in 2025 falls to a loss once those costs are counted. The improvement has been steady: gross margin rose from 69% to 71% in 2025 and reached 72.8% in the second quarter of 2026, when the net loss was close to zero. We estimate 2026 at roughly -$20 million, leaving out the one-time $50 million patent settlement paid to Baxter on July 31, 2026. Because each earlier year describes a much smaller, sub-scale business, we start the valuation from the 2025 level and the half of 2026 already reported, not from an average of older losses. How we valued it. We discount future owner cash flows at a flat 6%. All of the value comes from two things the record supports: continued growth in test volume, and the share of each new revenue dollar that has actually reached the bottom line. From 2023 to 2025, owner earnings improved by about 30 cents for each extra dollar of revenue (14 cents in 2025, 54 cents in 2024, and about 39 cents in the first half of 2026). We did not credit the pending VitalConnect acquisition ($237.5 million cash plus about $50 million in stock, not yet closed), the Zio MCT product the company hopes to have cleared in 2027, or management's adjusted-EBITDA targets. None of these has happened yet, and adjusted EBITDA leaves out costs we count. Base case, about $72 per share. Revenue grows about 18-19% in 2026, which is largely already booked. Growth then slows each year, from 12% in 2027 to zero by 2036, well below the 23% a year the company has grown over the past five years. We allow this because adoption by health systems, with 80 of the top 100 customers linking Zio into their electronic health records, has built up account by account for more than a decade, and it kept growing through the 2020 pandemic. Each new revenue dollar adds 30 cents of owner earnings. Owner earnings turn positive in 2027 and reach about $174 million (11% of about $1.5 billion revenue) by 2036. After that we hold them flat, with no further growth, supported by the established reimbursement codes, the favorable 2026 Medicare coverage decisions and the embedded customer base. Year-one check: in 2025 the loss narrowed by about $21 million on 26% revenue growth. The base case assumes a $32 million improvement in 2027 on just 12% growth. The reason for the larger step is the first half of 2026: net loss improved by $31 million on 23% growth, and the FDA has cleared a third-generation algorithm that is expected to cut technician review time. Bear case, about zero. The company has operated under an FDA warning letter on Zio AT since May 2023, received further FDA inspection observations in July 2024, and has faced a Justice Department investigation since 2021, with a civil document demand in April 2023. In 2022 a competitor paid $44.9 million to settle claims over offshore processing of Medicare heart-monitor work, and iRhythm itself uses offshore vendors and a Philippines team. Insurer denials rose in 2025. In this case growth drops to 7% in 2027 and stops by 2031, only 20 cents of each new revenue dollar reaches owners, a $60 million regulatory or legal resolution is paid in 2027, and refinancing the $661 million of 1.5% convertible notes due 2029 costs about $15 million a year in extra interest. Owner earnings barely break even and then fade under pressure on administered Medicare prices. The business is worth roughly nothing to shareholders in this case. That is because it never earns a meaningful surplus, not because its debts exceed a positive value. Bull case, about $178 per share. Growth runs at 18% in 2027 and tapers to 3% by 2036, still below the company's own record. The new algorithm and the higher gross margin lift the bottom-line share of new revenue to 35%. Owner earnings reach about $437 million (20% of about $2.2 billion revenue). The notes' capped-call hedge covers dilution up to $218 per share, so no dilution adjustment is needed at this value. What would make this wrong. The whole value rests on the company proving it can produce real cash profits after stock pay. It has not yet done so for a full year. An escalation of the FDA matter, such as a consent decree or restrictions on shipping Zio, or a cut to Medicare payment rates like the 2021 contractor repricing the industry went through, would move the result toward the bear case. So would a large acquisition that uses up the cash needed to repay the 2029 notes. On the other side, if growth holds near 20% for several more years with the current cost discipline, the base case will prove too cautious.